Nat Biotechnol:RNAi疗法减轻先兆子痫

2018-11-25 小通 生物通

来自麻省大学医学院、贝斯以色列女执事医学中心和西悉尼大学的科学家合作研究表明,使用小干扰RNA新型疗法(siRNA)在动物模型中减轻了先兆子痫症状。

来自麻省大学医学院、贝斯以色列女执事医学中心和西悉尼大学的科学家合作研究表明,使用小干扰RNA新型疗法(siRNA)在动物模型中减轻了先兆子痫症状。


Ananath Karumanchi


Melissa Moore

这项研究由麻省大学医学院Anastasia Khvorova和Melissa Moore博士以及贝斯以色列女执事医学中心和哈佛医学院的Ananath Karumanchi医学博士领导,提示RNA干扰疗法可能是治疗先兆子痫的一种潜在策略。

“对于先兆子痫的妇女来说,多怀孕几周就会对婴儿健康产生巨大影响,” RNA治疗学教授Khvorova说。“由于siRNA的快速发展,我们开发了一种siRNA,它使先兆子痫的妇女能够将妊娠期从24或25周延长到30周,结果婴儿得到了极大改善。”

先兆子痫是妊娠期高血压疾病,先兆子痫没有治愈或适当的治疗选择。患有先兆子痫的妇女从怀孕20周左右开始出现高血压和尿中过多的蛋白质,称为蛋白尿。在严重病例中,红细胞会破裂,血小板计数下降,肝和肾功能受损,液体会充满肺部,导致呼吸急促,增加母婴风险。在美国,2~8%的妊娠并发症中,先兆子痫每年导致10万早产和10000多名婴儿死亡。对该疾病的唯一治疗是娩出婴儿和胎盘。

先兆子痫的症状起因于在胎盘缺陷,该缺陷与血液中sFLT1蛋白的异常高水平相关,该蛋白充当抑制新血管生长的开关。减少循环sFLT1水平被认为是一种对该疾病有用的治疗靶点。

这项发表在 Nature Biotechnology杂志的研究表明,短干扰RNAs或siRNA可用于减少妊娠小鼠血液中sFLT1。siRNA是一类以核酸为目标的新兴药物,它能够降解信使RNA(mRNAs),mRNA携带DNA遗传信息,指导蛋白质合成。通过减少特定DNA序列的mRNA数量,科学家可以减少获得的成熟蛋白质的数量。当靶向编码sFLT1信使RNA的siRNA被传递给怀孕的小鼠时,循环蛋白质水平可降低高达50%。

联合悉尼大学医学院医学院院长Annemarie Hennessy博士,研究人员在怀孕的狒狒中测试了这种方法,这是一种人类先兆子痫临床前模型。研究人员发现,单次注射siRNA可以降低循环sFLT1水平,并使母亲的高血压和蛋白尿正常化。“六年前,这是不可能的,”Khvorova说。“现在科学上的进展使我们能够化学稳定地生产siRNA,从而将它们输送到肝外的组织中,这些进展已导致这些化合物的迅速崛起。我们正在开发的先兆子痫化合物预示着siRNA疗法的未来不可限量。”

Moore博士是麻省大学医学院的RNA治疗学教授,15年前,在被诊断为先兆子痫并被要求参与该疾病的研究之后,开始研究先兆子痫。

“这个项目在我的心里非常珍贵,” Moore说。“尽管这些结果令人兴奋,但我们还是觉得我们只是完成了一半。直到我们能给妇女们治病,它才是完整的。怀孕不应该是女人所做的最危险的事情之一。”

尽管该疗法改善了母婴健康,研究者也注意到了后代出生体重降低的趋势,这表明这种方法对新生儿健康的影响还需要更详细地研究,然后才能进入临床试验。研究人员的下一步是吸引资金用于进一步优化siRNA化学配置和广泛测试安全性所需的必要研究,这些研究是在申请美国食品和药物管理局(FDA)的研究性新药(IND)应用之前所必需的。

原始出处:Turanov AA, Lo A, Hassler MR, et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat Biotechnol. 2018 Nov 19.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=900817, encodeId=5ebb90081e61, content=<a href='/topic/show?id=370215539f6' target=_blank style='color:#2F92EE;'>#RNAi疗法#</a>减轻<a href='/topic/show?id=fe13285e6d9' target=_blank style='color:#2F92EE;'>#先兆子痫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15539, encryptionId=370215539f6, topicName=RNAi疗法), TopicDto(id=28576, encryptionId=fe13285e6d9, topicName=先兆子痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 20 15:45:27 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927698, encodeId=469f192e698bc, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Apr 15 20:22:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883440, encodeId=c33318834402c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 13 14:22:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918418, encodeId=71b819184188b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 02 08:22:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652306, encodeId=1714165230610, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Feb 24 19:22:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751665, encodeId=33a91e516652c, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Tue Sep 03 17:22:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353605, encodeId=a44c353605af, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Nov 25 09:05:54 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353584, encodeId=b3f63535844b, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Nov 25 06:18:01 CST 2018, time=2018-11-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=900817, encodeId=5ebb90081e61, content=<a href='/topic/show?id=370215539f6' target=_blank style='color:#2F92EE;'>#RNAi疗法#</a>减轻<a href='/topic/show?id=fe13285e6d9' target=_blank style='color:#2F92EE;'>#先兆子痫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15539, encryptionId=370215539f6, topicName=RNAi疗法), TopicDto(id=28576, encryptionId=fe13285e6d9, topicName=先兆子痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 20 15:45:27 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927698, encodeId=469f192e698bc, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Apr 15 20:22:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883440, encodeId=c33318834402c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 13 14:22:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918418, encodeId=71b819184188b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 02 08:22:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652306, encodeId=1714165230610, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Feb 24 19:22:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751665, encodeId=33a91e516652c, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Tue Sep 03 17:22:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353605, encodeId=a44c353605af, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Nov 25 09:05:54 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353584, encodeId=b3f63535844b, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Nov 25 06:18:01 CST 2018, time=2018-11-25, status=1, ipAttribution=)]
    2019-04-15 cathymary
  3. [GetPortalCommentsPageByObjectIdResponse(id=900817, encodeId=5ebb90081e61, content=<a href='/topic/show?id=370215539f6' target=_blank style='color:#2F92EE;'>#RNAi疗法#</a>减轻<a href='/topic/show?id=fe13285e6d9' target=_blank style='color:#2F92EE;'>#先兆子痫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15539, encryptionId=370215539f6, topicName=RNAi疗法), TopicDto(id=28576, encryptionId=fe13285e6d9, topicName=先兆子痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 20 15:45:27 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927698, encodeId=469f192e698bc, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Apr 15 20:22:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883440, encodeId=c33318834402c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 13 14:22:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918418, encodeId=71b819184188b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 02 08:22:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652306, encodeId=1714165230610, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Feb 24 19:22:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751665, encodeId=33a91e516652c, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Tue Sep 03 17:22:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353605, encodeId=a44c353605af, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Nov 25 09:05:54 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353584, encodeId=b3f63535844b, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Nov 25 06:18:01 CST 2018, time=2018-11-25, status=1, ipAttribution=)]
    2019-09-13 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=900817, encodeId=5ebb90081e61, content=<a href='/topic/show?id=370215539f6' target=_blank style='color:#2F92EE;'>#RNAi疗法#</a>减轻<a href='/topic/show?id=fe13285e6d9' target=_blank style='color:#2F92EE;'>#先兆子痫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15539, encryptionId=370215539f6, topicName=RNAi疗法), TopicDto(id=28576, encryptionId=fe13285e6d9, topicName=先兆子痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 20 15:45:27 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927698, encodeId=469f192e698bc, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Apr 15 20:22:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883440, encodeId=c33318834402c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 13 14:22:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918418, encodeId=71b819184188b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 02 08:22:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652306, encodeId=1714165230610, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Feb 24 19:22:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751665, encodeId=33a91e516652c, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Tue Sep 03 17:22:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353605, encodeId=a44c353605af, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Nov 25 09:05:54 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353584, encodeId=b3f63535844b, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Nov 25 06:18:01 CST 2018, time=2018-11-25, status=1, ipAttribution=)]
    2019-07-02 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=900817, encodeId=5ebb90081e61, content=<a href='/topic/show?id=370215539f6' target=_blank style='color:#2F92EE;'>#RNAi疗法#</a>减轻<a href='/topic/show?id=fe13285e6d9' target=_blank style='color:#2F92EE;'>#先兆子痫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15539, encryptionId=370215539f6, topicName=RNAi疗法), TopicDto(id=28576, encryptionId=fe13285e6d9, topicName=先兆子痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 20 15:45:27 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927698, encodeId=469f192e698bc, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Apr 15 20:22:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883440, encodeId=c33318834402c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 13 14:22:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918418, encodeId=71b819184188b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 02 08:22:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652306, encodeId=1714165230610, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Feb 24 19:22:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751665, encodeId=33a91e516652c, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Tue Sep 03 17:22:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353605, encodeId=a44c353605af, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Nov 25 09:05:54 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353584, encodeId=b3f63535844b, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Nov 25 06:18:01 CST 2018, time=2018-11-25, status=1, ipAttribution=)]
    2019-02-24 shock_melon
  6. [GetPortalCommentsPageByObjectIdResponse(id=900817, encodeId=5ebb90081e61, content=<a href='/topic/show?id=370215539f6' target=_blank style='color:#2F92EE;'>#RNAi疗法#</a>减轻<a href='/topic/show?id=fe13285e6d9' target=_blank style='color:#2F92EE;'>#先兆子痫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15539, encryptionId=370215539f6, topicName=RNAi疗法), TopicDto(id=28576, encryptionId=fe13285e6d9, topicName=先兆子痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 20 15:45:27 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927698, encodeId=469f192e698bc, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Apr 15 20:22:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883440, encodeId=c33318834402c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 13 14:22:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918418, encodeId=71b819184188b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 02 08:22:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652306, encodeId=1714165230610, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Feb 24 19:22:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751665, encodeId=33a91e516652c, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Tue Sep 03 17:22:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353605, encodeId=a44c353605af, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Nov 25 09:05:54 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353584, encodeId=b3f63535844b, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Nov 25 06:18:01 CST 2018, time=2018-11-25, status=1, ipAttribution=)]
    2019-09-03 yinxm8315
  7. [GetPortalCommentsPageByObjectIdResponse(id=900817, encodeId=5ebb90081e61, content=<a href='/topic/show?id=370215539f6' target=_blank style='color:#2F92EE;'>#RNAi疗法#</a>减轻<a href='/topic/show?id=fe13285e6d9' target=_blank style='color:#2F92EE;'>#先兆子痫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15539, encryptionId=370215539f6, topicName=RNAi疗法), TopicDto(id=28576, encryptionId=fe13285e6d9, topicName=先兆子痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 20 15:45:27 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927698, encodeId=469f192e698bc, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Apr 15 20:22:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883440, encodeId=c33318834402c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 13 14:22:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918418, encodeId=71b819184188b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 02 08:22:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652306, encodeId=1714165230610, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Feb 24 19:22:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751665, encodeId=33a91e516652c, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Tue Sep 03 17:22:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353605, encodeId=a44c353605af, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Nov 25 09:05:54 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353584, encodeId=b3f63535844b, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Nov 25 06:18:01 CST 2018, time=2018-11-25, status=1, ipAttribution=)]
    2018-11-25 龙胆草

    学习谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=900817, encodeId=5ebb90081e61, content=<a href='/topic/show?id=370215539f6' target=_blank style='color:#2F92EE;'>#RNAi疗法#</a>减轻<a href='/topic/show?id=fe13285e6d9' target=_blank style='color:#2F92EE;'>#先兆子痫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15539, encryptionId=370215539f6, topicName=RNAi疗法), TopicDto(id=28576, encryptionId=fe13285e6d9, topicName=先兆子痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 20 15:45:27 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927698, encodeId=469f192e698bc, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Apr 15 20:22:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883440, encodeId=c33318834402c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 13 14:22:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918418, encodeId=71b819184188b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 02 08:22:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652306, encodeId=1714165230610, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Feb 24 19:22:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751665, encodeId=33a91e516652c, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Tue Sep 03 17:22:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353605, encodeId=a44c353605af, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Nov 25 09:05:54 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353584, encodeId=b3f63535844b, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Nov 25 06:18:01 CST 2018, time=2018-11-25, status=1, ipAttribution=)]
    2018-11-25 yjs木玉

    学习学习再学习

    0

相关资讯

eLife:挑战常规!利用CRISPR-Cas9突变证实癌基因MELK其实并不致癌

MELK抑制剂正在接受测试的多种癌症之一是急性淋巴细胞白血病(ALL)。图片来自James Grellier/Wikimedia。 2017年3月29日/生物谷BIOON/---根据一项新的研究,一种被认为是癌细胞必需的蛋白,即母系胚胎亮氨酸拉链蛋白激酶(maternal embryonic leucine zipper kinase, MELK),可能实际上并不是如此必需的。来自

FDA批准**RNAi药物Onpattro用于治疗hATTR

日前,美国FDA批准了一项具有里程碑意义的基因疗法,针对罕见病遗传性转甲状腺素蛋白淀粉样变性或hATTR(一种神经病变或神经损伤)的基因疗法。这也是全球第一例依据诺贝尔奖成果RNA干扰技术开发的药物Onpattro,该药作用机理通过使致病基因“沉默”,进而从根本上治愈该罕见遗传疾病。也是FDA批准的首款小干扰RNA(siRNA)药物。hATTR影响了全球约50000人,是一种罕见、使人衰弱且常

Alnylam的RNAi疗法Onpattro获得欧盟批准治疗hATTR

Alnylam Pharmaceuticals于本周四宣布,该公司开发的Onpattro(patisiran)的获得欧盟的上市许可,用于治疗遗传性转甲状腺素蛋白淀粉样变性(hATTR)的1或2期多发性神经病变的成年患者。该公司指出,该药物在2018年8月11日被FDA批准后,现在再次获得欧盟批准,成为欧盟批准的首个RNAi疗法。

Oncotarget:肿瘤"小杀器",保护RNAi免受降解的阳离子液晶纳米粒子CLCN

研究人员开发了一种新型的阳离子液晶纳米粒子(CLCN),其是一种独特和先进的递送系统,能够保护RNAi免受降解,有效地在体外和体内递送合成的siRNA和miRNA。

20年等待!FDA批准基于诺奖技术的新疗法

8月10日,美国FDA宣布批准第一款基于RNA干扰(RNAi)技术的治疗药物——patisiran,适用于一种损伤心脏、神经功能的罕见病。其中,RNAi技术可以针对性沉默与疾病相关的特定基因,从而阻止致病蛋白的表达。

Science:重磅!RNAi是细胞静止所必需的

一些细胞并没有得到应有的重视。事实上,大多数细胞都没有。在我们的地球上,99%以上的细胞存在于一种静止状态中。捧起一把泥土:它含有上千种微生物,而且当被放置到培养皿中时,几乎每种微生物都不会生长。这些细胞是有代谢活性的---是的,活的---但是它们不会发生细胞分裂。它们将保持在一种繁殖上的“静止”状态,除非在特定条件下被激活从而再次进入细胞周期和准备再次分裂。 我们体内的一些重要的细胞事实上是静